Analyst consensus rating
Castle Biosciences Analyst Rating: Strong Buy
CSTL is rated Strong Buy by 9 analysts with a $44.00 target. As of 2026-08-27.
Direct answer
Castle Biosciences's consensus rating is Strong Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $44.00.
Forecast evidence checked August 27, 2026.
Get free Castle Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $34.08
- Average price target
- $44.00
- High price target
- $57.00
- Low price target
- $35.00
- Low target gap
- +2.7%
- Target upside
- +29.1%
- High target gap
- +67.3%
- Target range width
- 64.6%
- Consensus rating
- Strong Buy
- Analysts
- 9
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Castle Biosciences?
Castle Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $44.00.
How far are Castle Biosciences's low and high targets from the recorded price?
The low target implies +2.7%, while the high target implies +67.3%.
How many analysts are included in Castle Biosciences's consensus?
The verified consensus includes 9 analysts.
How is Castle Biosciences's target upside or downside calculated?
The average target of $44.00 is divided by the recorded price of $34.08, then one is subtracted to produce +29.1%. This does not guarantee a future return.
When was Castle Biosciences's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.